Drugs / Hydroquinone
Hydroquinone
also known as
4% Hydroquinone Topical Cream · Black and white bleaching cream · CHEBI:17594 · CHEMBL537 · Eldopaque forte · Eldopinone · Eldoquin forte · hydrochinon · +7 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TRI-LUMA | — | 2002-01-18 | fda.gov ↗ |
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06013540 | Aug → Dec 2022 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase 2 | NCT05119413 | Nov 2021 → Sep 2022 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Completed | Missed primary |
| Phase 2 | NCT03049059 | Jun → Dec 2016 | hyperpigmentation of the skin | Mae Fah Luang University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00975312 | Aug → Nov 2008 | lentigo | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06010810 | Jun → Sep 2023 | hyperpigmentation of the skin | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT05969587 | Nov 2019 → Sep 2020 | hyperpigmentation of the skin | China Medical University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02095990 | Mar → Aug 2014 | hyperpigmentation of the skin | Mesoestetic Pharma Group S.L. | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07696806 | Jul 2026 → Jun 2027 expected | hyperpigmentation of the skin | Sameh Sarsik | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT00472966 | Nov 2006 → Apr 2007 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT00469183 | May 2006 → Apr 2007 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07071363 | Jun → Oct 2025 overdue | hyperpigmentation of the skin | Laboratoire Dermatologique ACM | Recruiting | No outcome recorded |
| — | NCT06780644 | Feb → May 2025 overdue | hyperpigmentation of the skin | Indonesia University | Not yet recruiting | No outcome recorded |
| — | NCT06516419 | Feb 2024 → Mar 2025 overdue | hyperpigmentation of the skin | Indonesia University | Recruiting | No outcome recorded |
| — | NCT05013801 | Sep 2021 → Feb 2022 | hyperpigmentation of the skin | Unilever R&D | Completed | No outcome recorded |
| — | NCT02153697 | Mar → Oct 2014 | lentigo | University of Zurich | Completed | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 1 | NCT05887219 Comparator | Nov 2022 → Apr 2023 | hyperpigmentation of the skin | Combined Military Hospital Abbottabad | Completed | No outcome recorded |
| Phase 2 | NCT06957834 Comparator | Jun 2023 → Jul 2024 | hyperpigmentation of the skin | National Skin Centre | Completed | No outcome recorded |
| Phase 2 | NCT05511948 Comparator | Aug 2022 → Mar 2023 | hyperpigmentation of the skin | DermBiont, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03982849 Comparator | Jul → Dec 2019 | hyperpigmentation of the skin | Islamabad Medical and Dental College | Completed | No outcome recorded |
| Phase 2 | NCT01085279 Comparator | Mar 2009 → Feb 2010 | skin pigmentation disorder | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 2/3 | NCT00717652 Comparator | Jul 2008 | hyperpigmentation of the skin | Azidus Brasil | Suspended | No outcome recorded |
| Phase 3 | NCT03585179 Comparator | Aug 2018 → Dec 2019 | hyperpigmentation of the skin | Centro Dermatológico Dr. Ladislao de la Pascua | Unknown | No outcome recorded |
| Phase 3 | NCT03751163 Comparator | Mar 2016 → Apr 2017 | hyperpigmentation of the skin | Faculty of Medicine, University of Indonesia | Completed | No outcome recorded |
| Phase 4 | NCT07508098 Comparator | Jul 2025 → Jan 2026 | hyperpigmentation of the skin | Pak Emirates Military Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07676994 Comparator | May → Dec 2025 | hyperpigmentation of the skin | Ghurki Trust and Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04875715 Comparator | Jul 2021 → Dec 2026 expected | skin pigmentation disorder | University of California, Davis | Recruiting | No outcome recorded |
| Phase 4 | NCT02138539 Comparator | Oct 2013 → Oct 2014 | hyperpigmentation of the skin | Sadick Research Group | Completed | No outcome recorded |
| Phase 4 | NCT01661556 Comparator | Oct 2011 → Feb 2015 | hyperpigmentation of the skin | Autonomous University of San Luis Potosí | Unknown | No outcome recorded |
| Phase 4 | NCT00927771 Comparator | Jun 2009 → Jun 2010 | hyperpigmentation of the skin | Callender Center for Clinical Research | Unknown | No outcome recorded |
| Phase 4 | NCT00863278 Comparator | Mar 2009 → Mar 2010 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Terminated | No outcome recorded |
| Phase 4 | NCT00669071 Comparator | Jan → Oct 2008 | hyperpigmentation of the skin | Galderma R&D | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT07485777 Comparator | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07121439 Comparator | Sep → Nov 2025 overdue | hyperpigmentation of the skin | Indonesia University | Not yet recruiting | No outcome recorded |
| — | NCT07327983 Comparator | May → Nov 2025 | hyperpigmentation of the skin | Gujranwala medical college District Headquarters Hospital, Gujranwala | Completed | No outcome recorded |
| — | NCT07345507 Comparator | Feb → Aug 2025 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| — | NCT06787846 Comparator | Aug 2023 → Mar 2024 | hyperpigmentation of the skin | Cosmetique Active International | Completed | No outcome recorded |
| — | NCT05710068 Background | Dec 2021 → Aug 2022 | hyperpigmentation of the skin | Ajou University School of Medicine | Completed | No outcome recorded |
| — | NCT04597203 Comparator | Oct 2020 → Jan 2021 | hyperpigmentation of the skin | Mahidol University | Unknown | No outcome recorded |
| — | NCT02977507 Comparator | Dec 2016 → Oct 2017 | hyperpigmentation of the skin | Allergan | Completed | No outcome recorded |
| — | NCT03040089 Background | Mar → Jul 2016 | hyperpigmentation of the skin | CynosureLutronic | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 41 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroquinone | “Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around...” NCT06516419 ↗38“Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1...” NCT06780644 ↗ “Participants received modified Kligman's formula consisting of hydroquinone 4%, tretinoin 0.05%, and mometasone furoate 0.1% immediately after standardized microneedling with a...” NCT07696806 ↗ “The goal of this clinical trial is to compare 3% Topical Tranexamic Acid with 4% Topical Hydroquinone as Therapy of Melasma in Patients with Skin Type III-V.” NCT06010810 ↗ “The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.” NCT00975312 ↗ “Kligman's trio (KT), combining hydroquinone, retinoic acid and corticosteroid, is considered as the gold standard treatment of melasma.” PMID 37620285 ↗ Sep 2023 “Kligman's regimen - a combination of hydroquinone, tretinoin, and fluocinolone acetonide - remains the gold standard for treatment” NCT07485777 ↗ “Kligman's formula (trio) is a drug containing 5% hydroquinone, 0.1% retinoic acid and 0.1% dexamethason” NCT07676994 ↗ “The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.” NCT00863278 ↗ “Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks” NCT01085279 ↗ “5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months” NCT05710068 ↗ |
| Known as | 4% Hydroquinone Topical Cream | “4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.” NCT02977507 ↗ |
| Known as | Black and white bleaching cream | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | CHEBI:17594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | CHEMBL537 | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | Eldopaque forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | Eldopinone | “hydroquinone 4% cream (Eldopinone)” NCT07071363 ↗ |
| Known as | Eldoquin forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | hydrochinon | “Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.” NCT02153697 ↗ |
| Known as | Hydroquinone component of tri-luma | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | Melanoderm 4% | “Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study” NCT02095990 ↗ |
| Known as | Melanoderm 4% Crema | “To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face” NCT02095990 ↗ |
| Known as | Melquine | “4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co.,...” NCT05969587 ↗ |
| Known as | NCI-C55834 | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | NSC-9247 | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Known as | Solaquin forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL537 ↗ |
| Action | Inhibit | “Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.” NCT03982849 ↗ |
| Modality | Small molecule | — CHEMBL537 ↗ |
| Route | Topical | “Apply topically daily for 12 weeks” NCT00469183 ↗ |